A trial looking at sacituzumab tirumotecan for triple negative breast cancer

This trial is looking at sacituzumab tirumotecan on its own and in combination with pembrolizumab for triple negative breast cancer.

It is open to people who have triple negative breast cancer that:

• has come back in the same area and cannot be removed with surgery

• has spread to another part of the body and cannot be treated with the aim to cure

You pronounce sacituzumab tirumotecan as sass-ih-too-zo-mab tie-rum-o-tee-can.